EU – Approving Icaridin as an Existing Active Substance for Use in Biocidal Products of Product-Type 19

​ Commission Delegated Regulation (EU) No 1062/2014 establishes a list of existing active substances to be evaluated for their possible approval for use in biocidal products. That list includes icaridin which has been evaluated for use in product-type 19, repellents and attractants – Products used to control harmful organizms (invertebrates such as fleas, vertebrate such as birds, fish, rodents), by repelling or attracting, including those that are used for human or veterinary hygiene either directly on the skin or indirectly in the environment of humans or animals. As this active substance / product-type combination can satisfy the requirement of Article 5 of Directive 98/8/EC, provided that certain specifications and conditions concerning their use are complied with, icaridin is approved as an active substance for use in biocidal products of product-type 19, subject to the specifications and conditions set out as follows: Common Name: Icaridin IUPAC Name / Identification Numbers: (RS)-sec-butyl (RS)-2-(2-hydroxyethyl)piperidine-1-carboxylate EC No.: 423-210-8 CAS No.: 119515-38-7 Minimum degree of purity of the active substance: 97% w/w Date of Approval: 1 February 2022 Expiry date of approval: 31 January 2032 Product type: 19 Specific conditions: The authorisations of biocidal products are subject to the following conditions: (a) the product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance; (b) for products that may lead to residues in food and feed, the need to set new or to amend existing maximum residue levels (MRLs) in accordance with Regulation (EC) No 470/2009 of the European Parliament and of the Council or Regulation (EC) No 396/2005 of the European Parliament and of the Council shall be verified, and any appropriate risk mitigation measures shall be taken to ensure that the applicable MRLs are not exceeded; (c) in view of the risks identified for the uses assessed, the product assessment shall pay particular attention to children younger than two years following dermal and secondary exposure​